CR20190091A - Preparación farmacéutica anti-envejecimiento - Google Patents
Preparación farmacéutica anti-envejecimientoInfo
- Publication number
- CR20190091A CR20190091A CR20190091A CR20190091A CR20190091A CR 20190091 A CR20190091 A CR 20190091A CR 20190091 A CR20190091 A CR 20190091A CR 20190091 A CR20190091 A CR 20190091A CR 20190091 A CR20190091 A CR 20190091A
- Authority
- CR
- Costa Rica
- Prior art keywords
- liquid
- production method
- cellular constituents
- exosomes
- method further
- Prior art date
Links
- 230000003712 anti-aging effect Effects 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 abstract 18
- 230000001413 cellular effect Effects 0.000 abstract 8
- 239000000470 constituent Substances 0.000 abstract 8
- 238000004519 manufacturing process Methods 0.000 abstract 8
- 210000001808 exosome Anatomy 0.000 abstract 6
- 238000011534 incubation Methods 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se refiere a una preparación farmacéutica para su uso en el tratamiento de tratamiento o como agente antienvejecimiento, que puede prepararse mediante un método de producción que comprende los siguientes pasos: proporcionar un líquido recogido de un organismo, cuyo líquido comprende constituyentes celulares de la sangre, y un recipiente o medio de contención y poner en contacto dicho líquido con dicho recipiente o medio de contención, en donde (i) dicho método de producción comprende además la etapa de incubar dicho líquido en dicho recipiente o medio de contencón, y opcionalmente eliminar los constituyentes celulares de dicho líquido después de dicha incubación, (ii) dicho líquido comprende exosomas, y dicho método de producción comprende además las etapas de concentrar dichos exosomas y opcionalmente eliminar los constituyentes celulares de dicho líquido después de dicha concentración, o la etapa de aislar dichos exosomas, o (iii) dicho método de producción comprende además la etapa de evitar la incubación de dicho líquido, y la etapa de eliminar los constituyentes celulares de dicho líquido en contacto con dicho recipiente o medio de contenciónThe present invention relates a pharmaceutical preparation for use in the treatment of ageing or as an anti-ageing agent, which is preparable by a production method comprising the following steps: providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, and a vessel or containment means and contacting said liquid with said vessel or containment means, wherein (i) said production method further comprises the step of incubating said liquid in said vessel or containment means, and optionally removing cellular constituents of said liquid after said incubation, (ii) said liquid comprises exosomes, and said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or (iii) said production method further comprises the step of avoiding incubation of said liquid, and the step of removing cellular constituents of said liquid contacted with said vessel or containment means
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001807 | 2016-08-17 | ||
| PCT/EP2016/001888 WO2017080669A1 (en) | 2015-11-13 | 2016-11-14 | Pharmaceutical preparation effective in age-related disorders |
| PCT/EP2016/001887 WO2017080668A1 (en) | 2015-11-13 | 2016-11-14 | Pharmaceutical preparation effective in age-related disorders |
| PCT/EP2017/000581 WO2018033227A1 (en) | 2016-08-17 | 2017-05-12 | Anti-ageing pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190091A true CR20190091A (es) | 2019-05-07 |
Family
ID=61196401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190139A CR20190139A (es) | 2016-08-17 | 2017-05-11 | Preparación farmacéutica anti envejecimiento |
| CR20190091A CR20190091A (es) | 2016-08-17 | 2017-05-12 | Preparación farmacéutica anti-envejecimiento |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190139A CR20190139A (es) | 2016-08-17 | 2017-05-11 | Preparación farmacéutica anti envejecimiento |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20190290689A1 (es) |
| EP (4) | EP3695845A1 (es) |
| JP (2) | JP2019528281A (es) |
| KR (2) | KR20190049690A (es) |
| CN (2) | CN108348548A (es) |
| AU (2) | AU2017313163B2 (es) |
| BR (2) | BR112019002080A2 (es) |
| CA (2) | CA3033045A1 (es) |
| CL (2) | CL2019000419A1 (es) |
| CO (2) | CO2019001232A2 (es) |
| CR (2) | CR20190139A (es) |
| EA (2) | EA201890841A1 (es) |
| HK (3) | HK1255619A1 (es) |
| IL (2) | IL259007B1 (es) |
| MA (2) | MA42963A (es) |
| MX (2) | MX2019001948A (es) |
| PE (2) | PE20190627A1 (es) |
| PH (2) | PH12019550017A1 (es) |
| SG (2) | SG11201900866YA (es) |
| TW (2) | TW201806605A (es) |
| WO (3) | WO2018033226A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528281A (ja) * | 2016-08-17 | 2019-10-10 | オアトゲン アクチエンゲゼルシャフトＯＲＴＨＯＧＥＮ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 加齢防止製剤 |
| CN108841784A (zh) * | 2018-07-17 | 2018-11-20 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基 |
| EP3613424A1 (en) | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
| SG11202105579VA (en) * | 2018-12-27 | 2021-07-29 | Suntory Holdings Ltd | Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect |
| RU2695264C1 (ru) * | 2018-12-27 | 2019-07-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) | Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005262319A1 (en) * | 2004-07-01 | 2006-01-19 | Orthogen Ag | Immunosuppressive exosomes |
| DE102006005016A1 (de) * | 2006-02-03 | 2007-08-16 | Orthogen Ag | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
| DE202009017772U1 (de) * | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| WO2012076193A1 (de) * | 2010-12-10 | 2012-06-14 | Orthogen Ag | Kombinationspräparate mit exosomen und corticosteroid |
| EP3563859B1 (en) * | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| DE102012019088A1 (de) * | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
| CN103767985A (zh) * | 2012-10-22 | 2014-05-07 | 吉林省霍普金斯药物研究院有限责任公司 | 人源血液或间充质干细胞分泌exosome的制备与应用 |
| KR101784050B1 (ko) * | 2014-12-23 | 2017-10-10 | 영남대학교 산학협력단 | 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물 |
| CN105477016A (zh) * | 2015-11-13 | 2016-04-13 | 中国人民解放军第二军医大学 | 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用 |
| TW201722443A (zh) * | 2015-11-13 | 2017-07-01 | 奧爾托金公司 | 對老化相關病症有效之醫藥製劑 |
| CN105505854B (zh) * | 2016-01-14 | 2019-07-12 | 上海市第六人民医院 | 来源于人尿液细胞的外泌体的获取方法与应用 |
| CN105582576B (zh) * | 2016-02-23 | 2018-08-17 | 武汉大复生物科技有限公司 | 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途 |
| JP2019528281A (ja) * | 2016-08-17 | 2019-10-10 | オアトゲン アクチエンゲゼルシャフトＯＲＴＨＯＧＥＮ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 加齢防止製剤 |
-
2017
- 2017-05-11 JP JP2019508969A patent/JP2019528281A/ja active Pending
- 2017-05-11 PE PE2019000304A patent/PE20190627A1/es not_active Application Discontinuation
- 2017-05-11 WO PCT/EP2017/000574 patent/WO2018033226A1/en active Application Filing
- 2017-05-11 AU AU2017313163A patent/AU2017313163B2/en active Active
- 2017-05-11 CA CA3033045A patent/CA3033045A1/en active Pending
- 2017-05-11 BR BR112019002080-2A patent/BR112019002080A2/pt unknown
- 2017-05-11 EP EP20155846.7A patent/EP3695845A1/en active Pending
- 2017-05-11 IL IL259007A patent/IL259007B1/en unknown
- 2017-05-11 MA MA042963A patent/MA42963A/fr unknown
- 2017-05-11 KR KR1020197003441A patent/KR20190049690A/ko not_active Application Discontinuation
- 2017-05-11 US US16/325,870 patent/US20190290689A1/en not_active Abandoned
- 2017-05-11 CR CR20190139A patent/CR20190139A/es unknown
- 2017-05-11 EA EA201890841A patent/EA201890841A1/ru unknown
- 2017-05-11 EP EP17728051.8A patent/EP3352769A1/en not_active Withdrawn
- 2017-05-11 CN CN201780003804.9A patent/CN108348548A/zh active Pending
- 2017-05-11 SG SG11201900866YA patent/SG11201900866YA/en unknown
- 2017-05-11 MX MX2019001948A patent/MX2019001948A/es unknown
- 2017-05-12 CA CA3033899A patent/CA3033899A1/en not_active Abandoned
- 2017-05-12 AU AU2017313164A patent/AU2017313164B2/en active Active
- 2017-05-12 TW TW106115815A patent/TW201806605A/zh unknown
- 2017-05-12 MX MX2019001949A patent/MX2019001949A/es unknown
- 2017-05-12 BR BR112019002982-6A patent/BR112019002982A2/pt not_active Application Discontinuation
- 2017-05-12 CN CN201780003805.3A patent/CN108348549A/zh active Pending
- 2017-05-12 PE PE2019000361A patent/PE20190517A1/es not_active Application Discontinuation
- 2017-05-12 KR KR1020197004442A patent/KR20190046793A/ko unknown
- 2017-05-12 CR CR20190091A patent/CR20190091A/es unknown
- 2017-05-12 WO PCT/EP2017/000581 patent/WO2018033227A1/en active Application Filing
- 2017-05-12 JP JP2019508931A patent/JP2019529357A/ja active Pending
- 2017-05-12 SG SG11201901085RA patent/SG11201901085RA/en unknown
- 2017-05-12 EP EP17728052.6A patent/EP3352770A1/en not_active Withdrawn
- 2017-05-12 MA MA042964A patent/MA42964A/fr unknown
- 2017-05-12 TW TW106115816A patent/TW201806606A/zh unknown
- 2017-05-12 EA EA201890840A patent/EA201890840A1/ru unknown
- 2017-05-12 US US16/325,945 patent/US20210290671A1/en not_active Abandoned
- 2017-05-12 EP EP20163717.0A patent/EP3763377A1/en active Pending
- 2017-08-17 US US16/325,944 patent/US20190231816A1/en not_active Abandoned
- 2017-08-17 WO PCT/EP2017/000994 patent/WO2018033249A1/en active Application Filing
-
2018
- 2018-04-29 IL IL259006A patent/IL259006A/en unknown
- 2018-11-19 HK HK18114754.7A patent/HK1255619A1/zh unknown
-
2019
- 2019-01-22 HK HK19101111.1A patent/HK1259143A1/zh unknown
- 2019-01-22 HK HK19101113.9A patent/HK1258712A1/zh unknown
- 2019-01-30 PH PH12019550017A patent/PH12019550017A1/en unknown
- 2019-02-08 PH PH12019550022A patent/PH12019550022A1/en unknown
- 2019-02-12 CO CONC2019/0001232A patent/CO2019001232A2/es unknown
- 2019-02-13 CO CONC2019/0001265A patent/CO2019001265A2/es unknown
- 2019-02-15 CL CL2019000419A patent/CL2019000419A1/es unknown
- 2019-02-15 CL CL2019000420A patent/CL2019000420A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190091A (es) | Preparación farmacéutica anti-envejecimiento | |
| EP4300070A3 (en) | Culture patch, culture method, method and apparatus for testing culture, and method and apparatus for testing medicine | |
| MX342038B (es) | Metodo para monitorizar proceso de esterilizacion. | |
| WO2013036863A3 (en) | Efficient use of ionic liquids | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| MX366369B (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
| SG11201811521SA (en) | Method for preparing specimen for analysis or observation of skin | |
| MX2015008436A (es) | Composiciones para permeabilizar celulas sanguineos fijos y sus usos. | |
| MX2017001979A (es) | Metodo y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiologico simulado. | |
| BR112014028850A2 (pt) | medição cumulativa de um analito | |
| WO2013122611A3 (en) | New method for decontamination and processing of clinical specimens from a patient | |
| AR101088A1 (es) | Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano | |
| MX2022007856A (es) | Metodo perfeccionado para el analisis de un liquido con cuerpos en suspension. | |
| UA86128U (uk) | Спосіб оцінки електричних параметрів клітинних мембран біологічних тканин при механічних впливах | |
| MD111Z (ro) | Metodă de apreciere a viabilităţii protoscolexurilor echinococului in vitro | |
| EP3312291A4 (en) | Substrate solution for lipase activity measurement, and method and measurement reagent for measurement of lipase activity in sample | |
| UA98814U (en) | Method for biotin quantitative determination | |
| UA70773U (ru) | Способ диагностики острого криза отторжения почечного аллотрансплантата | |
| UA58977U (ru) | Способ прогнозирования цилиохориоидального отслоения после антиглаукоматозной операции | |
| AR070462A1 (es) | Metodo y composicion para tratar una afeccion diabetica. proceso para preparar dicha composicion. uso. | |
| UA74065U (ru) | Инверсионно-хронопотенциометрический способ определения никеля в водных растворах | |
| AR098655A1 (es) | Método de medición de viscosidad de gomas | |
| UA85276U (ru) | Способ диагностики состояния биологической ткани | |
| UA77210U (ru) | Способ изготовления гистологических срезов из тонкого фрагмента ткани | |
| PL396687A1 (pl) | Sposób otrzymywania estru dimetylowego kwasu 4-metylo-4-cyklohekseno-1,2-dikarboksylowego |